AQST
Aquestive Therapeutics, Inc.
Key Financials
Operating Income
$-71051000
↓ 130.9%
EPS (Diluted)
$-0.78
↓ 52.9%
Revenue
$44.5M
↓ 22.6%
Total Assets
$160.4M
↑ 58.2%
Cash & Equivalents
$31.8M
↓ 35.5%
Shareholders' Equity
$-33662000.00
↑ 44.0%
Total Liabilities
$194.1M
↑ 20.1%
Long-term Debt
$45.0M
0.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 8/18/2026 | View on SEC |
| 4 | 8/17/2026 | View on SEC |
| 144 | 8/17/2026 | View on SEC |
| 10-Q | 8/11/2026 | View on SEC |
| 8-K | 8/11/2026 | View on SEC |
| 8-K | 8/10/2026 | View on SEC |
| SCHEDULE 13G/A | 7/27/2026 | View on SEC |
| 4 | 7/17/2026 | View on SEC |
| 144 | 7/15/2026 | View on SEC |
| 424B3 | 7/9/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | AQST |
| Company Name | Aquestive Therapeutics, Inc. |
| CIK | 1398733 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 908-941-1900 |